Illumina (NASDAQ:ILMN) and Pressure Biosciences (OTCMKTS:PBIO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Risk & Volatility

Illumina has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Pressure Biosciences has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Profitability

This table compares Illumina and Pressure Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Illumina 24.79% 24.51% 13.53%
Pressure Biosciences -520.24% N/A -518.50%

Earnings & Valuation

This table compares Illumina and Pressure Biosciences’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Illumina $3.33 billion 13.96 $826.00 million $5.72 55.36
Pressure Biosciences $2.24 million 3.05 -$10.71 million N/A N/A

Illumina has higher revenue and earnings than Pressure Biosciences.

Analyst Recommendations

This is a summary of recent ratings for Illumina and Pressure Biosciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Illumina 0 3 12 0 2.80
Pressure Biosciences 0 0 0 0 N/A

Illumina currently has a consensus target price of $346.35, suggesting a potential upside of 9.38%. Given Illumina’s higher probable upside, analysts plainly believe Illumina is more favorable than Pressure Biosciences.

Insider & Institutional Ownership

90.5% of Illumina shares are held by institutional investors. 0.5% of Illumina shares are held by company insiders. Comparatively, 15.9% of Pressure Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Illumina beats Pressure Biosciences on 9 of the 11 factors compared between the two stocks.

About Illumina

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. has a partnership with Lundbeck Foundation GeoGenetics Centre for exploring the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

About Pressure Biosciences

Pressure BioSciences, Inc. develops pressure cycling technology (PCT) solutions. Its PCT technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations, including Barocycler 2320EXT, Barozyme-HT48, Barocycler NEP3229, HUB440, HUB880, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT-MicroCaps, PCT-Micro-Pestle, PULSE Tubes, and BaroFlex 8-well Processing Strips, as well as application specific kits. Pressure BioSciences, Inc. serves researchers at academic laboratories; government agencies; and biotechnology, pharmaceutical, and other life sciences institutions in the United States, Europe, and Asia. Pressure BioSciences, Inc. has a collaboration with NutraFuels, Inc. for the development of water-soluble Nanoemulsion-based nutraceuticals. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was founded in 1978 and is based in South Easton, Massachusetts.

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.